Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Operating Expenses (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Operating Expenses for 15 consecutive years, with $17.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 58.92% to $17.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.9 million, a 24.23% increase, with the full-year FY2025 number at $66.9 million, up 24.23% from a year prior.
  • Operating Expenses was $17.6 million for Q4 2025 at Niagen Bioscience, roughly flat from $17.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $19.4 million in Q3 2021 to a low of $11.1 million in Q4 2024.
  • A 5-year average of $15.4 million and a median of $15.1 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: tumbled 31.65% in 2022, then soared 58.92% in 2025.
  • Niagen Bioscience's Operating Expenses stood at $16.2 million in 2021, then dropped by 16.83% to $13.5 million in 2022, then fell by 2.64% to $13.1 million in 2023, then fell by 15.41% to $11.1 million in 2024, then soared by 58.92% to $17.6 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Operating Expenses are $17.6 million (Q4 2025), $17.7 million (Q3 2025), and $17.0 million (Q2 2025).